Abiomed Inc. (ABMD)
NASDAQ: ABMD
· Real-Time Price · USD
381.02
0.00 (0.00%)
At close: Dec 21, 2022, 10:00 PM
Abiomed Revenue Breakdown
| Period Ending | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 |
|---|---|---|---|---|
| Product Revenue | 984.54M | 41.2M | 34.06M | 27.73M |
| Product Revenue Growth | +2289.66% | +20.97% | +22.81% | n/a |
| Service And Other Revenue | 47.21M | n/a | n/a | n/a |
| Service And Other Revenue Growth | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 |
|---|---|---|---|---|
| Europe Revenue | 131.91M | 105.32M | 705.41M | 665.08M |
| Europe Revenue Growth | +25.25% | -85.07% | +6.06% | n/a |
| Japan Revenue | 51.69M | 42.87M | n/a | n/a |
| Japan Revenue Growth | +20.59% | n/a | n/a | n/a |
| Non Us Non Europe Non Japan Revenue | 10.54M | 691.58M | n/a | n/a |
| Non Us Non Europe Non Japan Revenue Growth | -98.48% | n/a | n/a | n/a |
| Outside The U.S Member Revenue | 194.14M | n/a | n/a | n/a |
| Outside The U.S Member Revenue Growth | n/a | n/a | n/a | n/a |
| United States Revenue | 837.61M | n/a | n/a | n/a |
| United States Revenue Growth | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 116.96M | 118M | 109.61M | 107.62M | 102.78M | 103.48M | 100.37M | 86.2M | 79.17M | 68.44M | 83.89M | 85.67M | 85.96M | 86.08M | 81.3M | 80.22M | 78.89M | 81.14M | 75.5M | 66.56M | 60.08M | 60.6M | 60.1M | 53.94M | 53.09M | 51.03M | 45.26M | 41.85M | 39.83M | 37.32M | 34.53M |
| Selling, General, and Administrative Revenue Growth | -0.88% | +7.66% | +1.85% | +4.71% | -0.68% | +3.10% | +16.45% | +8.88% | +15.67% | -18.41% | -2.08% | -0.33% | -0.14% | +5.88% | +1.34% | +1.68% | -2.77% | +7.47% | +13.44% | +10.78% | -0.85% | +0.83% | +11.43% | +1.60% | +4.02% | +12.76% | +8.13% | +5.08% | +6.71% | +8.07% | n/a |
| Research and Development Revenue | 42.09M | 40.48M | 43.78M | 40.87M | 41.04M | 37.71M | 31.99M | 33M | 30.52M | 26.36M | 25.35M | 25.66M | 23.97M | 23.79M | 25.55M | 23.96M | 22.72M | 21.27M | 21.27M | 17.71M | 19.39M | 16.93M | 16.32M | 16.35M | 18.05M | 15.66M | 14.22M | 13.76M | 11.57M | 10.21M | 9.85M |
| Research and Development Revenue Growth | +3.98% | -7.56% | +7.13% | -0.42% | +8.84% | +17.88% | -3.08% | +8.12% | +15.81% | +3.99% | -1.20% | +7.03% | +0.75% | -6.88% | +6.61% | +5.49% | +6.79% | +0.01% | +20.13% | -8.68% | +14.52% | +3.71% | -0.15% | -9.43% | +15.27% | +10.09% | +3.42% | +18.90% | +13.31% | +3.62% | n/a |